Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Anesth Analg. 2010 Oct;111(4):856-61. doi: 10.1213/ANE.0b013e3181ce1ffa. Epub 2010 Feb 8.
Unfractionated heparin's primary mechanism of action is to enhance the enzymatic activity of antithrombin (AT). We hypothesized that there would be a direct association between preoperative AT activity and both heparin dose response (HDR) and heparin sensitivity index (HSI) in patients undergoing coronary artery bypass graft surgery.
Demographic and perioperative data were collected from 304 patients undergoing primary coronary artery bypass graft surgery. AT activity was measured after induction of general anesthesia using a colorimetric method (Siemens Healthcare Diagnostics, Tarrytown, NY). Activated coagulation time (ACT), HDR, and HSI were measured using the Hepcon HMS Plus system (Medtronic, Minneapolis, MN). Heparin dose was calculated for a target ACT using measured HDR by the same system. Multivariate linear regression was performed to identify independent predictors of HDR. Subgroup analysis of patients with low AT activity (<80% normal; <0.813 U/mL) who may be at risk for heparin resistance was also performed.
Mean baseline ACT was 135 ± 18 seconds. Mean calculated HDR was 98 ± 21 s/U/mL. Mean baseline AT activity was 0.93 ± 0.13 U/mL. Baseline AT activity was not significantly associated with baseline or postheparin ACT, HDR, or HSI. Addition of AT activity to multivariable linear regression models of both HDR and HSI did not significantly improve model performance. Subgroup analysis of 49 patients with baseline AT <80% of normal levels did not reveal a relationship between low AT activity and HDR or HSI. Preoperative AT activity, HDR, and HSI were not associated with cardiac troponin I levels on the first postoperative day, intensive care unit duration, or hospital length of stay.
Although enhancing AT activity is the primary mechanism by which heparin facilitates cardiopulmonary bypass anticoagulation, low preoperative AT activity is not associated with impaired response to heparin or to clinical outcomes when using target ACTs of 300 to 350 seconds.
未分级肝素的主要作用机制是增强抗凝血酶(AT)的酶活性。我们假设,在接受冠状动脉旁路移植手术的患者中,术前 AT 活性与肝素剂量反应(HDR)和肝素敏感指数(HSI)之间存在直接关联。
从 304 例行择期冠状动脉旁路移植手术的患者中收集人口统计学和围手术期数据。在全身麻醉诱导后使用比色法(西门子医疗诊断,Tarrytown,NY)测量 AT 活性。使用 Hepcon HMS Plus 系统(美敦力,明尼苏达州明尼阿波利斯)测量激活凝血时间(ACT)、HDR 和 HSI。使用相同的系统,根据测量的 HDR 计算目标 ACT 的肝素剂量。进行多元线性回归分析,以确定 HDR 的独立预测因素。还对 AT 活性较低(<80%正常;<0.813 U/mL)的患者进行亚组分析,这些患者可能存在肝素抵抗的风险。
平均基线 ACT 为 135±18 秒。平均计算的 HDR 为 98±21 s/U/mL。平均基线 AT 活性为 0.93±0.13 U/mL。基线 AT 活性与基线或肝素后 ACT、HDR 或 HSI 均无显著相关性。将 AT 活性添加到 HDR 和 HSI 的多变量线性回归模型中并没有显著提高模型性能。对 49 名基线 AT 低于正常水平 80%的患者进行亚组分析,未发现低 AT 活性与 HDR 或 HSI 之间存在相关性。术前 AT 活性、HDR 和 HSI 与术后第 1 天的心肌肌钙蛋白 I 水平、重症监护病房持续时间或住院时间均无相关性。
尽管增强 AT 活性是肝素促进体外循环抗凝的主要机制,但当使用 300 至 350 秒的目标 ACT 时,低术前 AT 活性与肝素反应受损或临床结果无关。